PD 150606
目录号 : GC16912An inhibitor of calpains
Cas No.:179528-45-1
Sample solution is provided at 25 µL, 10mM.
PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 μM and 0.37 μM for mu- and m- calpains, respectively [1].
Calpain is an enzyme and plays an important role in a variety of physiological processes, including signaling, cytoskeletal remodeling, regulation of gene expression, apoptosis and cell cycle progression. It has been shown that calpain involves in many pathologies, like muscular dystrophies, cancer, diabetes, Alzheimer's disease and multiple sclerosis [2] [3].
PD 150606 is a potent calpain inhibitor and has similar activity as calpain inhibitor-III. When tested with A2058, A375 and HS578T cell lines infected with ΔPK(resulted the failure of cells growth in 3D culture), administration of PD 150606 in a concentration of 100 μM restored 3D growth in soft sugar culture by inhibiting calpain [2].
Treated pathogen-free adult C57BL/6 mice with PD 150606 (3 mg/kg, i.p) before LPS injection to establish sepsis mouse model that had lower myocardial calpain activity, the result showed that PD 150606 prevented the degradation of myocardial Hsp90/p-Akt protein induced by LPS and inhibited myocardial caspase-3 activation and apoptosis [3].
References:
[1]. Wang, K.K., et al., An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci U S A, 1996. 93(13): p. 6687-92.
[2]. Colunga, A., et al., Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to DeltaPK oncolytic activity in melanoma. Gene Ther, 2014. 21(4): p. 371-8.
[3]. Li, X., et al., The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. BMC Cardiovasc Disord, 2013. 13: p. 8.
Cas No. | 179528-45-1 | SDF | |
化学名 | (Z)-3-(4-iodophenyl)-2-sulfanylprop-2-enoic acid | ||
Canonical SMILES | C1=CC(=CC=C1C=C(C(=O)O)S)I | ||
分子式 | C9H7IO2S | 分子量 | 306.12 |
溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml,Ethanol: 2 mg/ml | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.2667 mL | 16.3335 mL | 32.6669 mL |
5 mM | 0.6533 mL | 3.2667 mL | 6.5334 mL |
10 mM | 0.3267 mL | 1.6333 mL | 3.2667 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet